Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 58, Issue 4, Pages 604-629Publisher
ELSEVIER
DOI: 10.1016/j.addr.2006.03.002
Keywords
thrombosis; myointimal hyperplasia (IH); gene delivery; endothelialization; endothelial cell (EC); vascular smooth muscle cell (SMC); extracellular matrix (ECM)
Categories
Funding
- NHLBI NIH HHS [F32 HL078151, F32 HL078151-01, F32 HL078151-02, R01 HL041272, F32 HL074594, R01-HL41272] Funding Source: Medline
Ask authors/readers for more resources
Atherosclerotic cardiovascular disease is a leading cause of death worldwide. Despite recent improvements in medical, operative, and endovascular treatments, the number of interventions performed annually continues to increase. Unfortunately, the durability of these interventions is limited acutely by thrombotic complications and later by myointimal hyperplasia followed by progression of atherosclerotic disease over time. Despite improving medical management of patients with atherosclerotic disease, these complications appear to be persisting. Cardiovascular gene therapy has the potential to make significant clinical inroads to limit these complications. This article will review the technical aspects of cardiovascular gene therapy; its application for promoting a functional endothelium, smooth muscle cell growth inhibition, therapeutic angiogenesis, tissue engineered vascular conduits, and discuss the current status of various applicable clinical trials. (c) 2006 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available